Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2020. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of December 31, 2019:
- Issued Share Capital: 5,383,102,231 Ordinary Shares of 25 pence each.
- Treasury Shares: 393,505,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,989,596,281.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in financial performance or capital structure.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,989,596,281) for compliance with disclosure thresholds.
- Confirm the count of treasury shares (393,505,950) held as of December 31, 2019.
- Note that this filing does not contain operational or financial results; refer to Form 20-F for comprehensive financial data.